9-Me-BC (9-methyl-β-carboline)

What this is

Obscure research chemical with intriguing but exclusively preclinical evidence. The Dresden group (Polanski; Reichmann; Gille) and Berlin Charité collaborators (Hamann; Wernicke; Bringmann; Rommelspacher) demonstrated dopaminergic neuroprotection in mouse Parkinson's models; Ostrowska 2020 (PMC8592951) showed doubled BDNF and ~3.2x Artemin expression in astrocyte culture plus MAO-A/B inhibition (IC50 ~1 μM / ~15.5 μM); Hamann 2012 (PMID 22380576) showed cognitive enhancement with hippocampal dendritic/synaptic proliferation. No human trials of any kind. Sold in gray-market nootropic shops with extravagant claims. Two safety caveats biohacker forums minimize: (1) the broader β-carboline class includes compounds that are co-mutagenic with aromatic amines, and (2) β-carbolines can bioactivate to N-methyl-β-carbolinium cations — structurally analogous to MPP+ (the active parkinsonian neurotoxin metabolized from MPTP). The latter is a theoretical chronic-use concern that has NOT been specifically ruled out for 9-Me-BC. Avoid until human safety data exist.

Mechanism

Mixed MAOI (MAO-A IC50 ~1 μM; MAO-B IC50 ~15.5 μM); proposed to stimulate dopaminergic neurogenesis and neuroprotection via BDNF and GDNF upregulation; dendritic and synaptic proliferation in rat hippocampus; PI3K/Akt anti-neuroinflammatory signaling in preclinical models; endogenous β-carboline also present in coffee; meats; and tobacco smoke

Dose & route

No established human dosing

Citations

• https://pubmed.ncbi.nlm.nih.gov/20682326/
• https://pubmed.ncbi.nlm.nih.gov/21094674/
• https://pubmed.ncbi.nlm.nih.gov/29704920/
• https://pubmed.ncbi.nlm.nih.gov/22380576/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC8592951/
• https://pubmed.ncbi.nlm.nih.gov/20374418/

Links go to the source. If a link is dead or you want something re-checked, let me know.